Medications for Advanced Renal Cell Carcinoma

2 results

  • bavencio

    (avelumab)
    EMD Serono, Inc.
    BAVENCIO (avelumab) is indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma, maintenance treatment of locally advanced or metastatic urothelial carcinoma after platinum chemotherapy, and first-line treatment of advanced renal cell carcinoma in combination with axitinib.

  • inlyta

    (axitinib)
    Pfizer Laboratories Div Pfizer Inc
    INLYTA is indicated for the first-line treatment of advanced renal cell carcinoma (RCC) in combination with avelumab or pembrolizumab. It is also approved as a single agent for treating advanced RCC after one prior systemic therapy failure.